Nipradilol protects rat retinal ganglion cells from apoptosis induced by serum deprivation in vitro and by diabetes in vivo

Current Eye Research

Volumn 33, Issue 8, 2008, Pages 683-692

  Tatsumi, Yasuko ^a   Kanamori, Akiyasu ^a   Nagai Kusuhara, Azusa ^a   Nakanishi, Yoriko ^a   Agarwal, Neeraj ^b   Negi, Akira ^a   Nakamura, Makoto ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Apoptosis; Diabetic retinopathy; Nipradilol; Nitric oxide; Protein kinase; Retinal ganglion cell

Indexed keywords

ANTIGLAUCOMA AGENT; CALCIUM; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; DENITRONIPRADILOL; GLUTAMIC ACID; NIPRADILOL; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA; RETINA GANGLION CELL; STREPTOZOCIN DIABETES;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; CALCIUM; CASPASE 3; CELL LINE; CELL SURVIVAL; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; IN SITU NICK-END LABELING; MALE; PROPANOLAMINES; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RETINAL GANGLION CELLS; SERUM; VASODILATOR AGENTS;

EID: 49549097621     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802323157     Document Type: Article

References (70)

1. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774-786.
2. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031-1035.
3. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102:783-791.
4. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41:764-774.
5. Ino-ue M, Zhang L, Naka H, Kuriyama H, Yamamoto M. Polyol metabolism of retrograde axonal transport in diabetic rat large optic nerve fiber. Invest Ophthalmol Vis Sci. 2000;41:4055-4058.
6. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AEB, Al-Shabrawey M, Platt DH, Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: Pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003;19:442-455.
7. Tezel G. Oxidative stress in glaucomatous neurodegeneration: Mechanisms and consequences. Prog Retin Eye Res. 2006;25:490-513.
8. Vorwerk CK, Gorla MS, Dreyer EB. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Surv Ophthalmol. 1999;43:Suppl 1, S142-S150.
9. Kowluru RA, Engerman RL, Case GL, Kern TS. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int. 2001;38:385-390.
10. McKinnon SJ, Lebman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, Ransom NL, Tahzib NG, Reitsamer HA, Leukovitch-Verbin H, Quigley HA, Zack DJ. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077-1087.
11. Barber AJ, Antonetti DA, Kern TS, Reiter CEN, Soans RS, Krady JK, Levinson SW, Gardner TW, Bronson SK. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci. 2005;46:2210-2218.
12. Uchida Y, Nakamura M, Shimizu S, Shirasawa Y, Fujii M. Vasoactive and beta-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3- isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351), a new antihypertensive agent. Arch Int Pharmacodyn Ther. 1983;262:132-149.
13. Ohira A, Wada Y, Fujii M, Nakamura M, Kasuya Y, Hamada Y, Shigenobu K. Effects of nipradilol (K-351) on alpha-adrenoceptor mediated responses in various isolated tissues. Arch Int Pharmacodyn Ther. 1985;278:61-71.
14. Kanno M, Araie M, Koibuchi H, Masuda K. Effects of topical nipradilol, a beta blocking agent with alpha blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans. Br J Ophthalmol. 2000;84:293-299.
15. Okamura T, Kitamura Y, Uchiyama M, Toda M, Ayajiki K, Toda N. Canine retinal arterial and arteriolar dilatation induced by nipradilol, a possible glaucoma therapeutic. Pharmacology. 1996;53:302-310.
16. Hayashi T, Yamada K, Esaki T, Muto E, Iguchi A. The beta adrenoceptor antagonist, nipradilol, preserves the endothelial nitric oxide response in atherosclerotic vessels in rabbit.Life Sci. 1997;61:1379-1387.
17. Mizuno K, Koide T, Saito N, Fujii M, Nagahara M, Tomidokoro A, Tamaki Y, Araie M. Topical nipradilol: Effect on optic nerve head circulation in humans and periocular distribution in monkeys. Invest Ophthalmol Vis Sci. 2002;43:3243-3250.
18. Kashiwagi K, Iizuka Y, Tsukahara S. Neuroprotective effect of nipradilol on purified cultured retinal ganglion cells. J Glaucoma. 2002;11:231-238.
19. Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a β-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci. 2001;42:688-694.
20. Nakazawa T, Tomita H, Yamaguchi K, Sato Y, Shimura M, Kuwahara S, Tamai M. Neuroprotective effect of nipradilol on axotomized rat retinal ganglion cells. Curr Eye Res. 2002;24:114-122.
21. Taniai M, Sato E, Mizota A, Adachi-Usami E. Protective action of nipradilol against ischemia-induced retinal damage in rats. Ophthalmic Res. 2002;34:331-337.
22. Tomita H, Nakazawa T, Sugano E, Abe T, Tamai M. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. Eur J Pharmacol. 2002;452:263-268.
23. Nagai-Kusuhara A, Nakamura M, Mukuno H, Kanamori A, Negi A, Seigel, GM. cAMP-responsive element binding protein mediates a cGMP/protein kinase G-dependent anti-apoptotic signal induced by nitric oxide in retinal neuro-glial progenitor cells. Exp Eye Res. 2007;84:152-162.
24. Krishnamoorthy RR, Agarwal P, Prasanna G, Vopat K, Lambert W, Sheedlo HJ, Pang IH, Shade D, Wordinger RJ, Yorio T, Clark AF, Agarwal N. Characterization of a transformed rat retinal ganglion cell line. Mol Brain Res. 2001;86:1-12.
25. Charles I, Khalyfa A, Kumar DM, Krishnamoorthy RR, Roque RS, Cooper N, Agarwal N. Serum deprivation induces apoptotic cell death of transformed rat retinal ganglion cells via mitochondrial signaling pathways. Invest Ophthalmol Vis Sci. 2005;46:1330-1338.
26. Maher P, Hanneken A. The molecular basis of oxidative stress-induced cell death in an immortalized retinal ganglion cell line. Invest Ophthalmol Vis Sci. 2005;46:749-757.
27. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci. 2000;17:463-471.
28. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci. 2004;45:3330-3336.
29. Ning X, Baoyu Q, Yuzhen L, Shuli S, Reed E, Li QQ. Neuro-optic cell apoptosis and microangiopathy in KKAY mouse retina. Int J Mol Med. 2005;13:87-92.
30. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, Chung SK. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes. 2005;54:3119-3125.
31. Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci. 2006;47:3143-3150.
32. Nakanishi Y, Nakamura M, Mukuno H, Kanamori A, Seigel G.M, Negi A. Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Exp Eye Res. 2006;83:1108-1117.
33. Barber AJ, Nakamura M, Wolpert EB, Reiter CEN, Seigel G.M, Antonetti DA, Gardner TW. Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of capase-3. J Biol Chem. 2001;276:32814-32821.
34. Nakamura M, Barber AJ, Antonetti DA, LaNoue KF, Robinson KA, Buse MG, Gardner TW. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. J Biol Chem. 2001;276:43748-43755.
35. Mukuno H, Nakamura M, Kanamori A, Nagai A, Negi A, Seigel GM. Unoprostone isopropyl rescues retinal progenitor cells from apoptosis in vitro. Curr Eye Res. 2004;29:457-464.
36. Kanamori A, Nakamura M, Mukuno H, Maeda H, Negi A. Diabetes has an additive effect on neural apoptosis in rat retina with chronically elevated intraocular pressure. Curr Eye Res. 2004;28:47-54.
37. Kanamori A, Nakamura M, Nakanishi Y, Nagai A, Mukuno H, Yamada Y, Negi A. Akt is activated via insulin/IGF-1 receptor in rat retina with episcleral vein cauterization. Brain Res. 2004;1022:195-204.
38. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. Am J Physiol. 1996;271:C1424-C1437.
39. Wink DA, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radical Biol Med. 1998;25:434-456.
40. Fiscus RR. Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neuronal cells. Neurosignals. 2002;11:175-190.
41. Boje KM. Nitric oxide neurotoxicity in neurodegenerative diseases. Front Biosci. 2004;9:763-776.
42. Kang Y-C, Kim P-K, Choi B-M, Chung H-T, Ha K-S, Kwon Y-G, Kim Y-M. Regulation of programmed cell death in neuronal cells by nitric oxide. In Vivo. 2004;18:367-376.
43. Keynes RG, Garthwaite J. Nitric oxide and its role in ischaemic brain injury. Curr Mol Med. 2004;4:179-191.
44. Duncan AJ, Heales SJR. Nitric oxide and neurological disorders. Mol Aspects Med. 2005;26:67-96.
45. Bolanos JP, Garcia-Nogales P, Almeida A. Provoking neuroprotection by peroxynitrite. Curr Pharm Des. 2004;10:867-877.
46. Taguchi R, Shirakawa H, Yamaguchi T, Kume T, Katsuki H, Akaike A. Nitric oxide-mediated effect of nipradilol and an α- and β-adrenergic blocker on glutamate neurotoxicity in rat cortical cultures. Eur J Pharmacol. 2006;535:86-94.
47. Farinelli SE, Park DS, Greene LA. Nitric oxide delays the death of trophic factor-deprived PC12 cells and sympathetic neurons by a cGMP-mediated mechanism. J Neurosci. 1996;16:2325-2334.
48. Kim Y-M, Chung H-T, Kim S-S, Han J-A, Yoo Y-M, Kim K-M, Lee G-H, Yun H-Y, Green A, Li L, Simmons RL, Billiar TR. Nitric oxide protects PC12 cells from serum deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling.J Neurosci. 1999;19:6740-6747.
49. Allsopp TE. Transduction of survival signals in neurons - take your PIK? Trends Neurosci. 2000;23:593.
50. Zhao H, Sapolsky RM, Steinberg GK. Phosphatidylinositol-3-kinase/akt survival signal pathways are implicated in neuronal survival after stroke. Mol Neurobiol. 2006;34:249-270.
51. Ha KS, Kim KM, Kwon YG, Bai SK, Nam WD, Yoo YM, Kim PK, Chung HT, Billiar TR, Kim YM. Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation. FASEB J. 2003;17:1036-1047.
52. Delgado-Esteban M, Martin-Zanca D, Andres-Martin L, Almedida A, Bolanos JP. J Neurochem. 2007;102:194-205.
53. Aviles-Trigueros M, Mayor-Torroglosa S, Garcia-Aviles A, Lafuente MP, Rodriguez ME, Miralles de Imperial J, Villegas-Perez MP, Vidal-Sanz M. Transient ischemia of the retina results in massive degeneration of the retinotectal projection: Long-term neuroprotection with brimonidine. Exp Neurol. 2003;184:767-777.
54. Manabe S, Lipton SA. Divergent NMDA signals leading to proapoptotic and antiapoptotic pathways in the rat retina. Invest Ophthalmol Vis Sci. 2003;44:385-392.
55. Tzekov R, Arden GB. The electroretinogram in diabetic retinopathy. Surv Ophthalmol. 1999;44:53-60.
56. Klemp K, Sander B, Brockhoff PB, Vaag A, Lund-Anderson H, Larsen M. The multifocal ERG in diabetic patients without retinopathy during euglycemic clamping. Invest Ophthalmol Vis Sci. 2005;46:2620-2626.
57. Verrotti A, Lobefalo L, Petitti MT, Mastropasqua L, Morgese G, Chiarelli F, Gallenga PE. Relationship between contrast sensitivity and metabolic control in diabetics with and without retinopathy. Ann Med. 1998;30:369-374.
58. Lopes de Faria JM, Katsumi O, Cagliero E, Nathan D, Hirose T. Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus. Graefes Arch Clin Exp Ophthalmol. 2001;239:643-648.
59. Chihara E, Matsuoka T, Ogura Y, Matsumura M. Retinal nerve fiber layer defect as an early manifestation of diabetic retinopathy. Ophthalmology. 1993;100:1147-1151.
60. Takahashi H, Goto T, Shoji T, Tanito M, Park M, Chihara E. Diabetes-associated retinal nerve fiber damage evaluated with scanning laser polarimetry. Am J Ophthalmol. 2006;142:88-94.
61. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Diabetes. 1998;47:815-820.
62. Rungger-Brandle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;41:1971-1980.
63. Barber AJ, Antonetti DA, Gardner TW. Altered expression of retinal occludin and glial fibrillary acidic protein in experimental diabetes. Invest Ophthalmol Vis Sci. 2000;41:3561-3568.
64. Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Muller cells. Invest Ophthalmol Vis Sci. 2002;43:3109-3116.
65. Gaucher D, Chiappore J-A, Pâques M, Simonutti M, Boitard C, Sahel JA, Massin P, Picaud S. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res. 2007;47:612-623.
66. Feit-Leichman RA, Kinouchi R, Takeda M, Fan Z, Mohr S, Kern TS, Chen DF. Vascular damage in a mouse model of diabetic retinopathy: Relation to neuronal and glial changes. Invest Ophthalmol Vis Sci. 2005;46:4281-4287.
67. Nakamura M, Kanamori A, Negi A. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. Ophthalmologica. 2005;219:1-10.
68. Chen W, Jump DB, Grant MB, Esselman WJ, Busik JV. Dyslipidemia, but not hyperglycemia, induces inflammatory adhesion molecules in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 2003;44:5016-5022.
69. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraemeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-1452.
70. Ono R, Kakehashi A, Ito Y, Sugi N, Makino S, Kobayashi E, Hakamada Y, Takagi Y, Kitazume Y, Kawakami M. Effect of topical nipradilol on retinal microvascular leukocyte adhesion in diabetic rats. Ophthalmic Res. 2006;38:270-273.